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ADAM-10 Is Overexpressed in Rheumatoid Arthritis
Synovial Tissue and Mediates Angiogenesis
Takeo Isozaki,1 Bradley J. Rabquer,2 Jeffrey H. Ruth,1
G. Kenneth Haines III,3 and Alisa E. Koch4
Objective. To examine the expression of ADAM-10
in rheumatoid arthritis (RA) synovial tissue (ST) and
the role it plays in angiogenesis.
Methods. ADAM-10 expression was determined
using immunohistology, Western blotting, and quanti-
tative polymerase chain reaction. In order to examine
the role of ADAM-10 in angiogenesis, we performed in
vitro Matrigel tube formation and chemotaxis assays
using human microvascular endothelial cells (HMVECs)
transfected with control or ADAM-10 small interfering
RNA (siRNA). To determine whether ADAM-10 plays a
role in angiogenesis in the context of RA, we performed
Matrigel assays using a coculture system of HMVECs
and RA synovial fibroblasts.
Results. Endothelial cells and lining cells within
RA ST expressed high levels of ADAM-10 compared
with cells within osteoarthritis ST and normal ST.
ADAM-10 expression was significantly elevated at the
protein and messenger RNA levels in HMVECs and RA
synovial fibroblasts stimulated with proinflammatory
mediators compared with unstimulated cells. ADAM-10
siRNA–treated HMVECs had decreased endothelial cell
tube formation and migration compared with control
siRNA–treated HMVECs. In addition, ADAM-10 siRNA–
treated HMVECs from the RA synovial fibroblast cocul-
ture system had decreased endothelial cell tube forma-
tion compared with control siRNA–treated HMVECs.
Conclusion. These data show that ADAM-10 is
overexpressed in RA and suggest that ADAM-10 may
play a role in RA angiogenesis. ADAM-10 may be a
potential therapeutic target in inflammatory angiogenic
diseases such as RA.
Rheumatoid arthritis (RA) is a systemic auto-
immune disease characterized by inflammation and
joint destruction (1). RA synovium contains high levels
of inflammatory cytokines and abundant inflammatory
cells, including infiltrating lymphocytes and monocytes
(2). Synovial tissue (ST) macrophages represent one of
the inflammatory cell types involved in RA pathogenesis.
ST macrophages produce several cytokines, such as
tumor necrosis factor  (TNF) and interleukin-1
(IL-1) (3,4). Extensive studies have identified TNF
as a key inflammatory mediator in RA, and treatment
of RA has been revolutionized by the introduction of
therapies blocking this cytokine. However, despite sup-
pression of this cytokine with anti-TNF therapy, not
all patients with RA experience improvement with such
treatment (5).
Angiogenesis is important in a variety of vascu-
loproliferative states, such as wound repair and RA
(6,7). Many inflammatory mediators are also angiogenic
mediators in RA ST and RA synovial fluid, including
IL-8/CXCL8 (7). The process of angiogenesis is often of
pivotal importance in disease progression and thus is an
interesting and promising therapeutic target (8).
ADAMs are a family of proteases that are re-
sponsible for the liberation of a variety of cell surface–
expressed proteins. ADAMs have been implicated in
several inflammatory and degenerative pathologic con-
ditions (9). ADAM-10 is involved in the shedding of
many substrates that play roles in cancer progression,
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allergic responses, and inflammatory disease (10–13). In
particular, ADAM-10 has been shown to cleave various
inflammatory and angiogenic mediators from the cell
surface, including fractalkine/CX3CL1 and CXCL16 (14,
15). Previous studies have shown that ADAM-15 and
ADAM-17 are active in RA. ADAM-15 messenger
RNA (mRNA) expression was higher in RA ST than in
osteoarthritis (OA) ST (16). Expression of ADAM-17 at
the protein level in RA ST was significantly higher than
that in OA ST (17). However, a direct role of ADAM-10
in RA has not been demonstrated. In this study, we sought
to define the function of ADAM-10 in RA angiogenesis.
MATERIALS AND METHODS
Cell culture. Dermal human microvascular endothelial
cells (HMVECs) were purchased from Lonza and were main-
tained in EBM Endothelial Basal Medium (Lonza). Fibro-
blasts were isolated from synovium obtained from patients
with RA who had undergone total joint replacement surgery
or synovectomy (18). The study was approved by the University
of Michigan Institutional Review Board. Fresh ST specimens
were minced and digested in a solution of Dispase, collage-
nase, and DNase (19). RA synovial fibroblasts were main-
tained in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS).
K/BxN mouse serum transfer–induced arthritis.
K/BxN mouse serum was collected at 7–8 weeks of age and
pooled (20). K/BxN mouse serum (150 l) was injected into
6–8-week-old mice on day 0 and day 2. All mice were killed on
day 12, the ankles were harvested for further examination, and
the joints were snap-frozen. Cryosections (10 m) of snap-
frozen joints from arthritic mice were used for immunohisto-
logic assays. All experiments on mice were approved by the
University Committee on the Use and Care of Animals at the
University of Michigan.
Immunohistologic analysis. We performed immuno-
histologic staining on cryosections from RA, OA, normal, and
psoriatic arthritis (PsA) ST, as described previously (21).
Rabbit anti-human ADAM-10 (25 g/ml; Abcam), ADAM-8
(10 g/ml; Novus Biologicals), ADAM-9 (5 g/ml; Novus
Biologicals), and ADAM-12 (5 g/ml; Novus Biologicals) were
used as a primary antibodies. We also used joints from mice
with K/BxN serum transfer–induced arthritis. Rabbit anti-
mouse ADAM-10 antibody (25 g/ml; Novus Biologicals) was
used as a primary antibody. Staining was evaluated by a
pathologist (GKH) who was blinded with regard to the sample
group. Slides were examined for cellular immunoreactivity,
and cell types were distinguished based on their characteristic
morphology. ST inflammation was assigned a score of 0 (least)
to 4 (most), depending on the degree of inflammatory cell
invasion. ST vascularity was assigned a score of 1 (least) to 4
(most), depending on the vessel density in the ST (21). The
percentage of cells expressing ADAM-8, ADAM-9, ADAM-
10, and ADAM-12 was analyzed on endothelial cells and lining
cells.
Cell lysis and Western blotting. HMVECs and RA
synovial fibroblasts were incubated in 6-well plates in 0.1%
FBS medium overnight, before stimulation with phorbol
myristate acetate (PMA; Sigma-Aldrich), lipopolysaccharide
(LPS) derived from Escherichia coli O111 (Sigma-Aldrich),
recombinant human interleukin-17 (rhIL-17), rhIL-1, or hu-
man rhTNF (all from R&D Systems). The concentrations of
the mediators that were used have been previously described
(22). Cell lysis and Western blotting were also performed as
previously described (21). Membranes were probed with rabbit
anti-human ADAM-10 antibody (Abcam). Densitometric analy-
sis of the bands was performed using Un-Scan-It software,
version 5.1 (Silk Scientific).
RNA extraction and quantitative reverse transcription–
polymerase chain reaction (RT-PCR). RNA extraction and
quantitative RT-PCR were performed as previously described
(23). The ADAM-10 and actin primer pairs were purchased
from Invitrogen. All samples were run in duplicate, and
Eppendorf software was used to analyze the read-out data.
RNA silencing. HMVECs were seeded in 6-well plates
at a density of 1  105 cells/well. The cells were maintained
in growth factor complete endothelial cell basal medium, at
which time they were 60–70% confluent. Small interfering
RNA (siRNA; 100 nM) against ADAM-10 or nonsilencing
siRNA and TransIT-TKO (Mirus) in 250 l serum-free endo-
thelial basal medium were mixed gently at room temperature
for 15 minutes to allow complexes to form. Thereafter, 1,250 l
of complete medium without antibiotics was added, and the
resultant solution was mixed and overlaid on the cells. Cells
were incubated with the siRNA and TransIT-TKO for 24 hours
at 37°C. Control and ADAM-10 siRNA were purchased from
Invitrogen. The target sequences of siRNA specific for
ADAM-10 or control were as follows: for ADAM-10-1, 5-
GAGGAAAUACCAGAUGACUGGUGUA-3; for ADAM-
10-2, 5-UACACCAGUCAUCUGGUAUUUCCUC-3; for
control, 5-GACCGAAUGGGUUCUAAGAAACACA-3.
The siRNA sequences for both ADAM-10-1 and ADAM-10-2
are provided in the same master mixture (Invitrogen). To
investigate the transfection efficiency of cells, fluorescein-
conjugated nonsilencing siRNA (Santa Cruz Biotechnology)
was transfected into cells with TransIT-TKO. The percent
knockdown of ADAM-10 expression was determined using
quantitative RT-PCR and Western blotting. In order to inves-
tigate whether knockdown was specific, we used quantitative
RT-PCR to assess the expression of ADAM-8, ADAM-9, and
ADAM-12.
Enzyme-linked immunosorbent assay (ELISA).
Ninety-six–well plates were coated with synovial fluid from
patients with RA, synovial fluid from patients with PsA, or
recombinant ADAM-10 (R&D Systems), which was used as a
standard. Goat anti-human ADAM-10 antibody (R&D Sys-
tems) was added as a primary antibody. The plates were then
washed, and biotinylated horse anti-goat antibody (Vector)
was added, followed by streptavidin–horseradish peroxidase
(streptavidin–HRP; BD Biosciences). The plates were devel-
oped using tetramethylbenzidine substrate (TMB; Sigma-
Aldrich) and were read on a microplate reader.
Ninety-six–well plates were coated with rabbit anti-
human CXCL16 antibody (PeproTech) or mouse anti-human
CX3CL1 antibody (R&D Systems). ADAM-10 siRNA– or
control siRNA–treatedHMVEC–conditionedmedium, recom-
binant CXCL16 (PeproTech), or CX3CL1 (R&D Systems),
used as a standard, was added. Biotinylated rabbit anti-human
CXCL16 antibody or mouse anti-human CX3CL1 antibody
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was used to detect CXCL16, using a streptavidin–peroxidase
method (BD Biosciences) with TMB. The concentration in
each sample was measured at 450 nm.
A direct ELISA was also developed using recombinant
soluble junctional adhesion molecule A (sJAM-A; R&D Sys-
tems) or sJAM-C (R&D Systems) as a standard, and 96-well
plates were coated with standard or samples overnight at 4°C.
The conditioned medium was added directly to the plate. Goat
anti-human JAM-A antibody (R&D Systems) or goat anti-
human JAM-C antibody (R&D Systems) was added as a
primary antibody. The plates were then washed, and biotinyl-
ated horse anti-goat antibody (Vector) was added, followed by
streptavidin–HRP (BD Biosciences). The plates were devel-
oped using TMB and were read on a microplate reader.
In vitro HMVEC chemotaxis assay. Chemotaxis assays
were performed using a 48-well modified Boyden chamber
system, as previously described (24,25). In order to confirm the
role of ADAM-10, we performed HMVEC chemotaxis assays
using recombinant ADAM-10 (100 nM; R&D Systems), con-
trol siRNA–transfected HMVEC–conditioned medium, and
ADAM-10 siRNA–transfected HMVEC conditioned medium.
HMVECs were transfected with control siRNA or
ADAM-10 siRNA, using TransIT-TKO. HMVECs treated
with control siRNA (100 nM) or ADAM-10 siRNA (100 nM)
were placed in the bottom wells of the chambers, and diluted
RA synovial fluid (1:10 in phosphate buffered saline [PBS])
was added to the top wells of the chambers. In addition, basic
fibroblast growth factor (bFGF; 60 nM) or vascular endothelial
growth factor (VEGF; 10 nM) (R&D Systems) was used as a
positive control. Readings represent the number of cells
migrating through the membrane (the sum of 3 high-power
fields/well, averaged for each quadruplicate well).
In vitro Matrigel tube formation assay. Matrigel tube
formation assays using growth factor–reduced Matrigel (BD
Biosciences) were performed (26,27). HMVECs were trans-
fected with control or ADAM-10 siRNA, using TransIT-TKO.
Basic FGF (10 nM) or VEGF (1 nM) was used as a positive
control, and PBS was used as a negative control. The treated
HMVECs (1.8  104 cells/400 l) were plated on Matrigel in
the presence of bFGF, VEGF, or PBS for 6 hours at 37°C.
Photographs (100 magnification) were obtained, and an ob-
server counted the tubes in a blinded manner. Tubes were
defined as elongated connecting branches between 2 identifi-
able HMVECs.
Endothelial cell tube formation assay using cocul-
tured HMVECs and RA synovial fibroblasts. In order to
confirm the influence of ADAM-10 on tube formation by
HMVECs, we cocultured HMVECs and RA synovial fibro-
blasts using a Transwell system (28). HMVECs were first
transfected, as described above, with either control siRNA or
ADAM-10 siRNA and were plated in the bottom of the
Transwell system. RA synovial fibroblasts were concurrently
grown on the top inserts. HMVECs and RA synovial fibro-
blasts were cocultured with serum-free medium for 24 hours.
HMVECs were collected from the coculture plates and subse-
quently plated on Matrigel in serum-free medium for 6 hours
at 37°C. Tubes formed by HMVECs were counted by an
observer in a blinded manner.
Conditioned medium from the coculture system was
then used in an in vitro Matrigel assay in which the medium
was added to HMVECs to determine whether tube formation
could be altered. To do this, HMVECs from the coculture
system were plated on Matrigel with the cocultured condi-
tioned medium for 6 hours at 37°C, and an observer counted
the number of tubes in a blinded manner.
Statistical analysis. Data were analyzed using Student’s
t-test, assuming equal variances. Data are reported as the
mean  SEM. P values less than 0.05 were considered
significant.
RESULTS
Expression of ADAM-10 on endothelial cells
and ST lining cells. We hypothesized that ADAM-10
is overexpressed in RA ST and plays a role in angiogen-
esis in RA. To test this hypothesis, we first determined
whether endothelial cells and RA synovial fibroblasts
could be induced to express ADAMs. ADAM expres-
sion was determined in RA, OA, normal, and PsA ST
samples and in the joints of mice with K/BxN serum–
transfer arthritis, using immunohistologic staining. Both
synovial inflammation and vascularity were significantly
increased in RA ST samples compared with OA and
normal ST samples (P  0.05; results not shown).
Figures 1A–D show representative photomicro-
graphs of sections stained for ADAM-10 or control IgG
antibody. Endothelial cells within RA ST expressed high
levels of ADAM-10 (mean  SEM 46  7%), while
endothelial cells within OA ST and normal ST expressed
significantly less ADAM-10 (9  3% and 1  1%,
respectively) (Figure 1I). Expression of ADAM-10 on
endothelial cells within PsA ST (n  1) was 2%.
However, there was no correlation between ADAM-10
expression and vascularity. ADAM-10 was highly ex-
pressed on lining cells in RA ST (72  6%), while lining
cells within OA ST and normal ST expressed signifi-
cantly less ADAM-10 (47  11% and 9  3%, respec-
tively) (Figure 1J). Expression of ADAM-10 on lining
cells within PsA ST was 4%. When experiments exam-
ining ADAM-8, ADAM-9, and ADAM-12 expression
were performed, no differences were observed between
RA ST and OA ST for any cell type (results not shown).
Figures 1E–H show the joints of mice with K/BxN
serum–induced arthritis and nonarthritic controls immu-
nostained with ADAM-10 or control IgG antibody.
ADAM-10 was overexpressed on lining cells in mice with
K/BxN serum–induced arthritis (day 12) compared with
mice without arthritis (day 0) (mean  SEM 64  6%
versus 21  11%) (Figure 1K). However, ADAM-10
expression on endothelial cells in the joints was not
different between the mice with K/BxN serum–induced
arthritis and the normal control group (0.5  0.2%
versus 0.1  0.1%).
Elevated ADAM-10 concentration in RA synovial
fluid compared with PsA synovial fluid. In order to
examine ADAM-10 secretion, we performed an
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ADAM-10 ELISA with synovial fluid. The ADAM-10
concentration in RA synovial fluid (n  17) was signif-
icantly elevated compared with that in PsA synovial fluid
(n  6) (mean  SEM 50  3 ng/ml and 37  3 ng/ml,
respectively) (Figure 1L).
Expression of ADAM-10 on HMVECs and RA
synovial fibroblasts. To determine whether ADAM-10
was expressed by endothelial cells and RA synovial cells
and whether its expression was regulated by proin-
flammatory cytokines or proangiogenic mediators,
Western blotting and quantitative PCR were performed.
ADAM-10 expression at the protein level was signifi-
cantly elevated on PMA-, LPS-, IL-17–, and TNF-
stimulated HMVECs compared with unstimulated en-
dothelial cells (Figure 2A). In addition, treatment with
LPS induced a 1.6-fold increase in the expression of
ADAM-10 mRNA in HMVECs within 1 hour (Figure
2B). ADAM-10 expression on RA synovial fibro-
blasts was inducible by IL-1 (Figure 2C). The expres-
sion of ADAM-10 mRNA was also significantly elevated
in IL-1–, IL-17–, PMA-, and LPS-stimulated RA syno-
vial fibroblasts compared with unstimulated cells
(Figure 2D).
ADAM-10–mediated release of potent angiogenic
factors. In order to confirm the function of ADAM-10,
we used siRNA directed against ADAM-10. The
mean  SEM transfection efficiency in HMVECs was
88  2% (n  3 replicates), and the percent knockdown
Figure 1. Immunohistologic analysis of ADAM-10. Endothelial cell (EC) and lining cell staining was graded from 0% to 100%, where 0% indicated
no staining and 100% showed that all the cells were immunopositive. A–D, Representative photomicrographs of synovial tissue (ST) samples from
patients with rheumatoid arthritis (RA). E and F, Representative photomicrographs of joints from mice with K/BxN serum–induced arthritis
(day 12). G and H, Representative photomicrographs of nonarthritic mouse joints (day 0). Cryosections were stained for ADAM-10 (A, C, E, and
G) or control IgG (B, D, F, and H). Arrows show ADAM-10 expression on endothelial cells (A) and ST lining cells (C and E). Original magnification
 400. I, ADAM-10 expression on RA ST, osteoarthritis (OA) ST, and normal (NL) ST endothelial cells. J, ADAM-10 expression on RA, OA, and
NL ST lining cells. K, ADAM-10 expression on ST lining cells from arthritic mouse joints (day 12) and nonarthritic mouse joints (day 0). L,
ADAM-10 concentration in RA synovial fluid and psoriatic arthritis (PsA) synovial fluid. Values in I–L are the mean  SEM.
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of ADAM-10 mRNA was 92  1% (n  3). The specific
knockdown of ADAM-10 was confirmed by Western
blotting, and ADAM-10 protein levels were shown to be
decreased (Figure 3A). To examine whether knockdown
was specific, we assayed for ADAM-8, ADAM-9, and
ADAM-12 mRNA and observed 7  9% knockdown of
ADAM-8 mRNA, 3  1% knockdown of ADAM-9
mRNA, and 0  0% knockdown of ADAM-12 mRNA
(n  3). We then tested whether ADAM-10 cleaves
potent angiogenic factors such as JAM-A, JAM-C,
CXCL16, and CX3CL1 from the cell surface. When
ADAM-10 was inhibited using siRNA, sJAM-A expres-
sion was decreased 17  2%, sJAM-C expression was
decreased 78 19%, CXCL16 expression was decreased
71  1%, and CX3CL1 expression was decreased 65 
9% (P  0.05; n  4 replicates) (Figures 3B–E).
Effect of ADAM-10 on angiogenesis. To deter-
mine the role of ADAM-10 in angiogenesis, we per-
Figure 2. ADAM-10 expression on human microvascular endothelial cells (HMVECs) and rheumatoid arthritis synovial fibroblasts. A, ADAM-10
expression in HMVECs, as determined by Western blotting. HMVECs were incubated for 24 hours with phorbol myristate acetate (PMA),
lipopolysaccharide (LPS), interleukin-17 (IL-17), IL-1, or tumor necrosis factor  (TNF), and the band intensities were quantified. A
representative blot is shown. B, ADAM-10 mRNA expression on HMVECs following stimulation with LPS, as determined by quantitative
polymerase chain reaction (PCR). C, ADAM-10 expression on RA synovial fibroblasts, as determined by Western blotting. RA synovial fibroblasts
were incubated for 72 hours with PMA, LPS, IL-17, IL-1, or TNF, and the band intensities were quantified. A representative blot is shown.
D, ADAM-10 mRNA expression on RA synovial fibroblasts following stimulation with TNF, IL-1, IL-17, PMA, and LPS, as determined by
quantitative PCR. Bars show the mean  SEM. n  number of experiments using cells from a single donor; NS  not stimulated.
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formed in vitro chemotaxis assays and Matrigel tube
formation assays. Endothelial cell chemotaxis is an ini-
tial step in the angiogenic process. HMVECs were
assayed for their chemotactic response to ADAM-10,
using a modified Boyden chamber. In order to de-
termine whether ADAM-10 mediates angiogenesis
directly or indirectly, we performed HMVEC chemo-
taxis toward recombinant human ADAM-10, control
siRNA–transfected HMVEC–conditioned medium, and
ADAM-10 siRNA–transfected HMVEC–conditioned
medium. HMVECs did not migrate toward recombi-
nant human ADAM-10. In contrast, ADAM-10 siRNA–
transfected HMVEC–conditioned medium caused a
significant decrease in the chemotactic potential for
HMVECs compared with control siRNA–transfected
HMVEC–conditioned medium (mean  SEM number
of HMVECs migrated 26  2 and 47  3, respectively;
P  0.05) (Figure 4A). ADAM-10 siRNA–treated
HMVECs showed decreased migration toward RA syno-
vial fluid compared with control siRNA (mean  SEM
number of HMVECs migrated 19  2 and 35  4,
respectively; P  0.05) (Figure 4B).
To confirm which mediators are important in
ADAM-10–induced angiogenesis, we used bFGF and
VEGF as chemotactic stimuli. ADAM-10 siRNA–
treated HMVECs showed decreased migration toward
bFGF compared with control siRNA–treated HMVECs
and untreated HMVECs (mean  SEM number of
HMVECs migrated 3  0, 8  1, and 12  1, respec-
tively; P 0.05) (Figure 4C). ADAM-10 siRNA–treated
HMVECs also had decreased migration toward VEGF
compared with control siRNA–treated HMVECs
and untreated HMVECs (mean  SEM number of
HMVECs migrated 5  1, 10  1, and 12  2,
respectively; P  0.05) (Figure 4D), indicating that both
bFGF and VEGF have important roles in ADAM-10–
induced angiogenesis.
ADAM-10 siRNA–treated HMVECs showed de-
Figure 3. Decreased ADAM-10 expression on HMVECS, using small interfering RNS (siRNA) directed against ADAM-10. Cells were stimulated
with TNF (25 ng/ml) for 24 hours. A, Representative Western blot showing ADAM-10 expression on ADAM-10 siRNA–treated HMVECs and
control siRNA–treated HMVECs. B–E, Expression of soluble junctional adhesion molecule A (sJAM-A) (B), sJAM-C (C), soluble CXCL16 (D),
and soluble CX3CL1 (E) on ADAM-10 siRNA– or control siRNA–treated HMVECs. Bars show the mean  SEM. n  number of replicates (see
Figure 2 for other definitions).
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creased endothelial cell tube formation in response to
bFGF compared with control siRNA–treated HMVECs
or untreated HMVECs (mean  SEM number of endo-
thelial cell tubes formed 2  1, 32  5, and 35  3,
respectively; P  0.05) (Figures 5A and B). In addition,
ADAM-10 siRNA–treated HMVECs showed decreased
endothelial cell tube formation in Matrigel in response
to VEGF compared with control siRNA–treated
HMVECs and untreated HMVECs (mean  SEM
number of endothelial cell tubes formed 4  1, 30  5,
and 27  3, respectively; P  0.05) (Figures 5C and D).
In order to examine the role of ADAM-10 in
angiogenesis with respect to RA, we used untreated
HMVECs, ADAM-10 siRNA–treated HMVECs, and
control siRNA–treated HMVECs and cocultured these
endothelial cells with RASFs in an in vitro chamber
system. ADAM-10 siRNA–treated HMVECs from the
coculture system showed decreased endothelial cell tube
formation compared with control siRNA–treated and
untreated HMVECs (mean SEM number of endothe-
lial cell tubes formed 4  2, 23  1, and 27  1,
respectively; P  0.05) (Figures 6A and B).
We also examined the possibility that fibroblasts
may affect HMVEC tube formation, potentially con-
founding our findings. To control for this possibility, we
added HMVECs obtained from the coculture system
Figure 4. Human microvascular endothelial cell (HMVEC) chemotaxis induced by ADAM-10. A, HMVEC chemotaxis toward recombinant human
ADAM-10 (rhADAM-10), control siRNA–transfected HMVEC–conditioned medium, and ADAM-10 siRNA–transfected HMVEC–conditioned
medium. HMVECs did not migrate toward recombinant ADAM-10. B, Contribution of ADAM-10 to rheumatoid arthritis (RA) synovial
fluid–mediated HMVEC chemotaxis. RA synovial fluid was depleted of rheumatoid factor, and HMVECs were treated with control small interfering
RNA (siRNA) or ADAM-10 siRNA. C, Contribution of ADAM-10 to basic fibroblast growth factor (bFGF)–mediated HMVEC chemotaxis. Basic
FGF (60 nM) was used as a stimulus for HMVEC chemotaxis. D, Contribution of ADAM-10 to vascular endothelial growth factor
(VEGF)–mediated HMVEC chemotaxis. VEGF (10 nM) was used as a stimulus for HMVEC chemotaxis. In A, C, and D, values are the mean 
SEM, and n  number of replicates. In B, bars show the mean of 4 separate adjacent wells, and n  number of RA synovial fluid samples used.
hpf  high-power field; PBS  phosphate buffered saline.
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directly to Matrigel containing RA synovial fibroblast–
conditioned medium and cultured them for 6 hours.
ADAM-10 siRNA–treated HMVECs from RA synovial
fibroblast–conditioned medium showed decreased endo-
thelial cell tube formation compared with control
siRNA–treated and untreated HMVECs (mean  SEM
Figure 5. Tube formation by untreated HMVECs and HMVECs treated with ADAM-10 siRNA or control siRNA. A and C, Representative images
showing HMVEC tube formation on Matrigel following stimulation with bFGF (A) and VEGF (C). Arrows indicate tube formation. Original
magnification  100. B and D, Quantification of HMVEC tube formation on Matrigel following stimulation with bFGF (B) and VEGF (D). Bars
show the mean  SEM. n  number of individual experiments (see Figure 4 for other definitions).
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Figure 6. Tube formation by human microvascular endothelial cells (HMVECs) cocultured with rheumatoid arthritis synovial fibroblasts. HMVECs
were first transfected with control or ADAM-10 small interfering RNA (siRNA) and plated in the bottom wells of the Transwell system wells. RA
synovial fibroblasts were grown on the top inserts of the Transwell system. The treated HMVECs were plated on Matrigel. A and C, Representative
images showing tube formation by untreated HMVECs and HMVECs treated with control siRNA or ADAM-10 siRNA (A) and HMVECs from
the RA synovial fibroblast coculture medium (C). Arrows indicate tube formation. Original magnification  100. B and D, Quantification of tube
formation by HMVECs from the coculture system (B) and HMVECs from the RA synovial fibroblast coculture medium (D). Bars show the mean
SEM. hpf  high-power field; n  number of RA synovial fibroblasts.
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number of endothelial cell tubes formed 7  2, 15  3,
and 25  2, respectively; P  0.05) (Figures 6C and D).
These results showed that RA synovial fibroblasts
were not involved in HMVEC tube formation, and that
transfected HMVECs that were unable to express
ADAM-10 had a reduced capacity to form tubes in vitro.
DISCUSSION
Angiogenesis is initiated by proangiogenic medi-
ators that promote the release of proteolytic enzymes,
including matrix metalloproteinases, resulting in the
degradation of endothelial cell basement membrane and
the perivascular extracellular matrix. In addition, spe-
cific angiogenic mediators activate endothelial cells and
induce their proliferation and migration. The activated
endothelial cells proliferate and migrate into the sur-
rounding area, thus forming primary sprouts. Our group
and others have previously shown that TNF and other
key mediators of RA pathogenesis, including fractalkine/
CX3CL1, CXCL16, JAM-A, and JAM-C, exist as cell
surface–expressed and soluble proteins (22,24,29). As
soluble factors, these mediators promote inflammation
and angiogenesis and thus drive the progression of RA.
ADAM-10 is a protease with a range of sub-
strates that play roles in cancer proliferation, inflam-
mation, and angiogenesis (30,31). These substrates in-
clude proinflammatory chemokines such as fractalkine/
CX3CL1 and CXCL16 (14,15). We previously demon-
strated that several of these ADAM-10 substrates are
up-regulated in RA ST or RA synovial fluid (24,32).
However, the expression and regulation of ADAM-10 in
RA have not been completely described. In the only
previous study of ADAM-10 in RA, Komiya et al
showed that ADAM-10 mRNA was found in RA ST at
levels similar to those in OA ST, but information
regarding localization of ADAM-10 expression in the
different ST cell types was not provided (16). Komiya
and colleagues showed that the mRNA levels of other
ADAMs, such as ADAM-8, ADAM-9, and ADAM-12,
are similar between RA and OA. The present study
clearly demonstrated that ADAM-10 is expressed on
both endothelial cells and lining cells in normal, OA, and
RA ST. In addition, the results showed that ADAM-10
was more highly expressed on endothelial cells and
lining cells in RA ST than on endothelial cells and lining
cells in OA and normal ST. We also observed that
ADAM-8, ADAM-9, and ADAM-12 expression was not
different between RA ST and OA ST.
Because of the more selective expression of
ADAM-10 in RA ST than in OA ST, we focused on
ADAM-10. In mice, ADAM-10 expression was signifi-
cantly increased on the lining cells of arthritic joints
compared with noninflamed control joints. In contrast,
ADAM-10 expression on endothelial cells was low in the
joints of both arthritic and nonarthritic mice. In addi-
tion, we observed that ADAM-10 expression was ele-
vated in RA synovial fluid compared with PsA synovial
fluid.
After observing ADAM-10 expression in RA ST
endothelial cells and RA synovial fibroblasts, we deter-
mined which mediators control the expression of
ADAM-10 in key cell types in RA ST. Western blotting
and quantitative PCR revealed increased amounts of
ADAM-10 expression on HMVECs and RA synovial
fibroblasts upon stimulation with proinflammatory me-
diators such as TNF, IL-1, IL-17, PMA, or LPS.
These data demonstrate the importance of both endo-
thelial cell– and fibroblast-expressed ADAM-10 expres-
sion in RA.
We observed that ADAM-10 is also important in
angiogenesis. Schulz et al showed that ADAM-10 ac-
tively plays a role in thrombin-induced decreases in
endothelial cell–endothelial cell interactions (10). Those
investigators reported that knockdown of ADAM-10
in human umbilical vein endothelial cells (HUVECs)
by siRNA impaired T cell transmigration. Glomski et al
studied ADAM-10–deficient mice and showed that
these mice had vascular abnormalities such as aberrant
subcapsular hepatic veins, enlarged glomeruli, intestinal
polyps containing endothelial cell masses, and abnormal
endochondral ossification (31). Donners et al showed
that VEGF induced ADAM-10–mediated cleavage of
VE-cadherin, which increases endothelial cell migration
(33). They also demonstrated that VEGF increased
vascular permeability in an ADAM-10–dependent man-
ner, and that inhibition of ADAM-10 decreased endo-
thelial cell migration.
After defining the activity of ADAM-10 using
HMVEC chemotaxis and tube formation assays, we next
assessed the role of ADAM-10 in angiogenesis with
respect to RA. Specifically, we assessed the ability of
ADAM-10 siRNA–transfected HMVECs cocultured
with RA synovial fibroblasts to form tube structures. In
general, coculture systems of normal dermal fibroblasts
and HUVECs are used for tube formation assays (34).
However, the RA joint is rich in angiogenic mediators. A
number of infiltrating cells contribute to the accumula-
tion of angiogenic factors, including T cells and mono-
cytes. In addition to these cells, resident ST lining
fibroblasts account for many of the pathologic and
clinical manifestations of RA (35). Moreover, fibroblasts
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produce many inflammatory and angiogenic mediators,
including cytokines and chemokines (36). Therefore, we
used RASFs to replicate the environment of the RA
joint.
We observed that ADAM-10 siRNA–treated
HMVECs had decreased endothelial cell tube forma-
tion activity compared with control siRNA–treated
HMVECs in coculture with RA synovial fibroblasts
or conditioned medium from the coculture system.
ADAM-10 siRNA–treated HMVECs stimulated with
bFGF or VEGF exhibited decreased migration com-
pared with control siRNA–treated HMVECs stimu-
lated with either bFGF or VEGF. We also controlled for
the possibility that soluble factors such as bFGF or
VEGF may be produced by RA synovial fibroblasts in
the coculture system. This was done by isolating the
treated HMVECs from the coculture system, washing
them, and incubating these cells on Matrigel. We ob-
served a decrease in tube-forming activity from the
ADAM-10 siRNA–treated endothelial cells similar to
that observed using the RA synovial fibroblast–
conditioned medium, confirming that the inhibitory
effect on tube formation is endothelial cell specific.
RA synovial fibroblasts secrete angiogenic factors
capable of inducing endothelial cell tube formation.
However, the reduction in tube formation could be
attributed to the lack of ADAM-10 expression in vitro.
Because ADAM-10 cleaves potent angiogenic factors
such as JAM-A, JAM-C, CXCL16, and CX3CL1 from
the cell surface (25,37–39), limiting cleavage of these
molecules via ADAM-10 inhibition may impair the
ability of endothelial cells to initiate angiogenesis. We
observed no HMVEC chemotaxis toward recombinant
ADAM-10. However, we observed that ADAM-10
siRNA–transfected HMVEC–conditioned medium in-
duced less HMVEC chemotaxis compared with control
siRNA–transfected HMVEC–conditioned medium.
This finding suggests that ADAM-10 mediates angio-
genesis indirectly. In addition, decreased ADAM-10–
mediated cleavage of adhesion molecules may result in
increased endothelial cell–endothelial cell interactions
mediated by JAMs, thus preventing migration of endo-
thelial cells. It would be interesting to examine these
mechanisms in an in vivo environment such as a murine
model of collagen-induced arthritis. Indeed, the finding
that ADAM-10 inhibits joint inflammation by reducing
vasculature would be novel and exciting. The in vitro
results presented here indicate that such a study would
be relevant and would validate the use of ADAM-10–
null mice to confirm our current findings.
We report here that ADAM-10 was overex-
pressed in RA ST. In addition, we demonstrated that
endothelial cells and ST lining cells are a source of
ADAM-10, and that proinflammatory mediators up-
regulate the expression of ADAM-10. Moreover, we
showed that ADAM-10 plays a very important role in
angiogenesis in RA.
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